Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2011 Apr;55(4):1768-70. doi: 10.1128/AAC.01577-10. Epub 2011 Jan 24.

Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.

Author information

1
Los Angeles Biomedical Research Institute, Division of Infectious Diseases, Harbor-UCLA Medical Center, 1124 West Carson St., St. John's Cardiovascular Research Center, Torrance, CA 90502, USA. ibrahim@labiomed.org

Abstract

Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and to a lesser extent with aspergillosis. Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted.

PMID:
21263057
PMCID:
PMC3067166
DOI:
10.1128/AAC.01577-10
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center